Vinod C Tawar
Clover Hill Medical Clinic, Canada
Title: Prostatic hypertrophy and cancer treatment review
Biography
Biography: Vinod C Tawar
Abstract
Benign prostatic hypertrophy is of common occurrence in a medical practice, seen in men of advanced age after 50 years. It also leads to obstructive voiding and cancer. Determination of PSA levels have been detection tool in the diagnosis. However, current studies have shown a lack of specificity. The relevance of hypertrophy or cancer in nephrology has been primarily, due to the presence of disease has to be ruled out in male kidney transplant donors. My primary interest in clinical research since 2016 on BPH and cancer has been on searching for safer treatment options e.g. topical formulations consisting 2 of PDE5 inhibitors (Papaverine and Sildenafil). The trials at pilot studies have shown relief from obstructive voiding symptoms, decrease in PSA levels, increased cavernous blood flow, and androgenic effects without a PSA rise. Current evidence has shown a decrease in pre-cancerous PC3 cells with Papaverine. My current research is targeting the assessment of this parameter at monthly intervals of the PDE5 inhibitors. The current literature review from 2015, to date has shown significant evidence supporting the benefit from Papaverine. Some authors have utilized injectable forms; however topical agents have been free of such complication.